Every year, an estimated 60-70 million people are affected by gastrointestinal diseases in the US alone.1 Across the world, novel therapies are desperately needed in both gastroenterology and hepatology. That’s where we come in.We have a dedicated, 800-strong Gastroenterology/Hepatology team who understand the broad spectrum of digestive disorders. Specializing in Phase I to IV studies, we help to bring a diverse range of therapies to an equally diverse range of markets, delivering projects ranging from strategic clinical development planning to single- or multi-phase clinical programs.Want your gastroenterology or hepatology clinical development program to get the best possible start in life? So do we. That’s why we work closely with gastroenterologists, hepatologists, primary care investigators and Key Opinion Leaders across the globe. It means you can be sure that the strategies we develop for you are built on the best network and knowledge in the business.

  • Our adult and pediatric clinical study experience includes:
  • Anal fissures
  • Celiac disease
  • Colitis
  • Colorectal disorders
  • Constipation disorders
  • Diverticulitis
  • Gastroenteritis
  • Gastroesophageal reflux disease (GERD)
  • Gastric surgery (including band devices)
  • Gastric ulcers
  • Hepatic cirrhosis/fibrosis
  • Inflammatory bowel disease (IBD) including Crohn’s Disease and ulcerative colitis
  • Irritable bowel syndrome (IBS)
  • NAFLD/NASH
  • Nausea and vomiting
  • Pancreatitis
  • Post-operative ileus
  • Short bowel syndrome

Let us help you give your clinical development program the best possible start in life. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136:376–386. [PubMed: 19124023] a This is an estimate of INC Research studies from the last five years that are completed or scheduled to complete for this therapy area.